REGULATORY MECHANISMS OF PROSTATE TUMOR PROGRESSION

前列腺的异常情况构成了一个主要的医疗问题， 美国的前列腺炎、良性增大（BPH）和恶性 前列腺（CaP）的生长，将影响大多数人的生活在过去的几年中， 50岁BPH是一种令人烦恼的异常生长，幸运的是， 有多种选择。前列腺癌，如果早期发现， 可治愈的然而，转移性疾病可能是致命的，如目前存在的， 对于转移性前列腺癌没有可用的治愈性疗法。此外，本发明还提供了一种方法， 因为在生物学潜力方面的极端异质性 前列腺癌的治疗方法存在争议，即使 局部疾病。目前缺乏共识和可行的办法， 管理和治疗。这反映出我们缺乏知识 关于负责这一光谱的生物决定因素， 行为的水平，将提供适当的治疗 干预 这个奥布莱恩泌尿外科中心项目将重点关注 确定与以下相关的细胞表型的变化： 疾病进展从正常到癌前病变，到局部 癌症和远距离传播疾病。在这个项目中，我们将 主要研究与细胞信号和细胞周期相关的三个领域 编程，因为它与良性和恶性前列腺生长有关。 第一个项目将集中研究细胞周期调控 前列腺癌的进展第二个项目将审查 PKC同工酶信号传导在转移进展中的改变， 细胞凋亡第三个项目将审查方案支助和管理司的作用 抗原作为前列腺生物学中的叶酸水解酶， 进化到癌症。这些项目和招聘发展 该中心的计划旨在提供对 生物学的进展，并制定强有力的合理性， 创新的干预战略。

Abnormal conditions or the prostate constitute a major medical problem in the United States. Prostatitis, benign enlargement (BPH), and malignant growth of the prostate (CaP), will effect the lives of most men over the age of 50. BPH is a bothersome abnormal growth that fortunately is readily treated by a variety of options. Prostate cancer, if detected early is curable. However, metastatic disease can be fatal, as there is currently no available curative therapy for metastatic prostate cancer. In addition, because of the extreme heterogeneity with regard to the biologic potential of prostatic cancer, there is debate on the approach to therapy, even with localized disease. There is a lack of consensus and viable approaches to management and therapy for CaP. This reflects our lack of knowledge regarding the biologic determinants responsible for this spectrum of behavior at a level that would provide appropriate therapeutic intervention. This O'Brien Urology Center project will focus its attention on determining changes in the cellular phenotype that is associated with disease progression from normal to premalignant lesions, to localized cancer, and to distant disseminated disease. In this project we will center on three areas related to cellular signaling and cell cycle programming as it related to benign and malignant prostate growth. The first project will focus its research efforts on cell cycle regulation in prostate cancer progression. The second project will examine alterations in PKC isozyme signaling in metastatic progression and in apoptotic cell death. The third project will examine the role of PSM antigen as a folate hydrolase in the biology of the prostate and its evolution to cancer. These projects and the recruitment of developmental programs to the Center are designed to provide an understanding of the biology of progression of CaP and developing strong rational for innovative interventional strategies.